Dr. Burkhard Blank Joins MannKind as Executive Vice President of Research & Development and Chief Medical Officer
May 24, 2023 08:30 ET
|
MannKind
DANBURY, Conn., May 24, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for...
MannKind Corporation to Participate in the 2023 RBC Capital Markets Global Healthcare Conference
May 10, 2023 06:00 ET
|
MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic...
CORRECTION -- MannKind Corporation Reports 2023 First Quarter Financial Results
May 09, 2023 20:21 ET
|
MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by MannKind Corporation (Nasdaq: MKND), please note in the...
Mannkind Corporation Reports 2023 First Quarter Financial Results
May 09, 2023 16:00 ET
|
MannKind
1Q 2023 Total Revenues of $41 million; +239% vs. 1Q 2022 1Q 2023 Revenues associated with Tyvaso DPI of $23 million 1Q 2023 Loss from operations decreased 72% vs. 1Q 2022 to $6 million $167 million of...
MannKind Corporation to Hold 2023 First Quarter Financial Results Conference Call on May 9, 2023
May 02, 2023 17:00 ET
|
MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2023 first quarter financial results and its management will host a...
Lauren Sabella Joins Mannkind as Executive Vice President, Chief Operating Officer
March 27, 2023 16:05 ET
|
MannKind
DANBURY, Conn., March 27, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for...
MannKind Corporation to Participate in Oppenheimer 33rd Annual Healthcare Conference
March 07, 2023 17:00 ET
|
MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic...
MannKind Corporation Reports 2022 Fourth Quarter and Full Year Financial Results
February 23, 2023 16:00 ET
|
MannKind
2022 Total Revenues of $100 million; +32% vs. 20212022 Royalties from Tyvaso DPI of $16 million; 4Q 2022 of $9 million4Q 2022 Commercial Products Net Revenue of $17 million;+54% vs. 4Q 2021$173...
MannKind to Give Oral Presentation on Meal Challenge Results From the Afrezza® With Basal Combination (ABC Study) at 16th Annual ATTD Conference
February 22, 2023 06:05 ET
|
MannKind
Inhaled Technosphere® Insulin (TI) lowered peak glucose levels 30 minutes faster than injectable rapid-acting insulin delivered through an AID insulin pump and significantly lowered post-prandial...
MannKind Corporation to Hold 2022 Fourth Quarter and Full Year Financial Results Conference Call on February 23, 2023
February 16, 2023 17:00 ET
|
MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2022 fourth quarter and full year financial results and its...